Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Jonathan I. Silverberg, MD, PhD, MPH / Eric Simpson, MD, MCR - Advancing Care for People Living With Moderate to Severe Atopic Dermatitis: The Future Looks Clear
Manage episode 295803867 series 2942795
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/KCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Over the past decade, the understanding of atopic dermatitis (AD) pathogenesis has evolved, giving way to numerous potential therapeutic targets. During this time, Janus kinase (JAK) inhibitors—a new class of medications—have also emerged. While the JAK-signal transducer and activator of transcription (JAK-STAT) pathway did not seem to be an obvious target early on, JAK inhibitors are likely to be the next generation of agents FDA approved for the treatment of moderate to severe AD. Indeed, JAK inhibitors are demonstrating benefit across multiple dermatologic diseases and constitute a promising frontier for dermatologic therapy overall. In this activity, based on a recent live web broadcast, our expert faculty examine the complex pathogenesis that underlies AD, focusing on the rationale for development of novel therapeutic approaches. In addition, key information (eg, mechanism of action, side-effect profiles, and dosing) for these new and emerging agents for moderate to severe AD will be provided, as well as the most up-to-date efficacy and safety data and practical considerations for clinical use. Upon completion of this accredited CE activity, participants should be better able to: Recognize recent insights into the pathogenesis of atopic dermatitis (AD) that have led to the development of new molecules targeting key cytokine signaling pathways, Evaluate recent safety and efficacy data related to emerging treatment options for moderate to severe AD, identifying potential implications for patient care, Develop strategies to identify candidates for newer therapeutic options and overcome barriers to achieving treatment goals in patients with moderate to severe AD.